Header Logo

Connection

JOSEPH JANKOVIC to Huntington Disease

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Huntington Disease.
JOSEPH JANKOVIC
Connection Strength
8.803
Huntington Disease
  1. Systemic Symptoms in Huntington's Disease: A Comprehensive Review. Mov Disord Clin Pract. 2024 May; 11(5):453-464.
    View in: PubMed
    Score: 0.816
  2. Clinical phenotype in carriers of intermediate alleles in the huntingtin gene. J Neurol Sci. 2019 Jul 15; 402:57-61.
    View in: PubMed
    Score: 0.582
  3. Huntington disease: A quarter century of progress since the gene discovery. J Neurol Sci. 2019 01 15; 396:52-68.
    View in: PubMed
    Score: 0.557
  4. Deutetrabenazine for the treatment of Huntington's chorea. Expert Rev Neurother. 2018 08; 18(8):625-631.
    View in: PubMed
    Score: 0.550
  5. Letter re: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2017 01 17; 88(3):334.
    View in: PubMed
    Score: 0.496
  6. Chorea associated with Huntington's disease: to treat or not to treat? Mov Disord. 2014 Sep 15; 29(11):1414-8.
    View in: PubMed
    Score: 0.420
  7. Huntington's disease: how intermediate are intermediate repeat lengths? Mov Disord. 2012 Dec; 27(14):1714-7.
    View in: PubMed
    Score: 0.368
  8. Exploring the correlates of intermediate CAG repeats in Huntington disease. Postgrad Med. 2011 Sep; 123(5):116-21.
    View in: PubMed
    Score: 0.341
  9. Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene. Mov Disord. 2011 Apr; 26(5):925-7.
    View in: PubMed
    Score: 0.330
  10. Advances in the pharmacological management of Huntington's disease. Drugs. 2010 Mar 26; 70(5):561-71.
    View in: PubMed
    Score: 0.309
  11. Psychogenic chorea associated with family history of Huntington disease. Mov Disord. 2010 Mar 15; 25(4):503-4.
    View in: PubMed
    Score: 0.308
  12. Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord. 2008 Dec 15; 23(16):2307-11.
    View in: PubMed
    Score: 0.283
  13. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008 May-Jun; 31(3):127-33.
    View in: PubMed
    Score: 0.271
  14. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008 Apr; 5(2):181-97.
    View in: PubMed
    Score: 0.269
  15. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007 Jan; 22(1):10-3.
    View in: PubMed
    Score: 0.247
  16. Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord. 2007 Jan; 22(1):127-30.
    View in: PubMed
    Score: 0.247
  17. Minocycline in Huntington's disease: a pilot study. Mov Disord. 2004 Jun; 19(6):692-5.
    View in: PubMed
    Score: 0.207
  18. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol. 2003 Jan-Feb; 26(1):18-23.
    View in: PubMed
    Score: 0.187
  19. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002 Nov-Dec; 25(6):300-2.
    View in: PubMed
    Score: 0.185
  20. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord. 2019 10; 67:74-89.
    View in: PubMed
    Score: 0.147
  21. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs. 2018 04; 78(5):525-541.
    View in: PubMed
    Score: 0.135
  22. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017 Jan 10; 88(2):152-159.
    View in: PubMed
    Score: 0.123
  23. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec; 17(18):2461-2470.
    View in: PubMed
    Score: 0.123
  24. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 05; 316(1):40-50.
    View in: PubMed
    Score: 0.119
  25. Cervical dystonia as the initial presentation of Huntington's disease. Mov Disord. 1996 Jul; 11(4):457-9.
    View in: PubMed
    Score: 0.119
  26. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10.
    View in: PubMed
    Score: 0.115
  27. Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet. 1995 Jul; 32(7):516-8.
    View in: PubMed
    Score: 0.111
  28. Tourettism associated with Huntington's disease. Mov Disord. 1995 Jan; 10(1):103-5.
    View in: PubMed
    Score: 0.108
  29. CAG repeat size and clinical presentation in Huntington's disease. Neurology. 1994 Jun; 44(6):1137-43.
    View in: PubMed
    Score: 0.103
  30. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology. 2013 May 28; 80(22):2022-7.
    View in: PubMed
    Score: 0.096
  31. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013 Feb; 28(2):210-5.
    View in: PubMed
    Score: 0.094
  32. Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci. 2012 Feb 15; 313(1-2):35-41.
    View in: PubMed
    Score: 0.086
  33. Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord. 2010 Dec; 16(10):628-38.
    View in: PubMed
    Score: 0.079
  34. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15; 22(2):193-7.
    View in: PubMed
    Score: 0.062
  35. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006 Jan; 6(1):7-17.
    View in: PubMed
    Score: 0.058
  36. Phenotypic features of Huntington's disease-like 2. Mov Disord. 2003 Dec; 18(12):1527-30.
    View in: PubMed
    Score: 0.050
  37. Bruxism in Huntington's disease. Mov Disord. 2000 Jan; 15(1):171-3.
    View in: PubMed
    Score: 0.038
  38. Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease. Am J Med Genet. 1996 Dec 18; 66(3):281-6.
    View in: PubMed
    Score: 0.031
  39. Chorea and ballism. Curr Opin Neurol Neurosurg. 1992 Jun; 5(3):308-13.
    View in: PubMed
    Score: 0.022
  40. Alcohol dehydrogenase polymorphism and Parkinson's disease. Neurosci Lett. 2001 Jun 01; 305(1):70-2.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.